Omalizumab Side Effects
The most critical side effect of omalizumab is anaphylaxis, occurring in approximately 0.09-0.2% of patients, with the unique characteristic that reactions can occur beyond the typical observation period—up to 24 hours or more after injection 1, 2.
Serious/Life-Threatening Reactions
Anaphylaxis
- Incidence: 0.09-0.2% of patients 1
- Timing is unpredictable:
- 35% occur within 30 minutes
- 16% between 30-60 minutes
- 14% between 6-12 hours
- 8% between 12-24 hours
- 5% between 24 hours to 4 days 2
- Can occur with any dose: 39% with first dose, 19% with second dose, but also reported after 39 doses following treatment gap 2
- Clinical presentation: Bronchospasm (89% of cases), hypotension/syncope (14%), urticaria, angioedema of throat/tongue, dyspnea, chest tightness 2
- Recurrence risk: 18 of 23 patients (78%) who were rechallenged experienced repeat anaphylaxis 2
Other Severe Reactions
- Eosinophilic conditions (mechanism: possible paradoxical immune activation) 2
- Serum sickness-like reactions: Arthritis/arthralgia, rash, fever, lymphadenopathy 2
- Severe thrombocytopenia 2
- Bullous erythema multiforme (extremely rare, reported 17 days post-injection) 3
Common Side Effects
Based on the largest real-world study of 1,859 patients, 32.9% reported side effects 4:
- Fatigue: 15.8% 4
- Headache: 11.6% 4
- Flu-like symptoms: 9.3% 4
- Hair loss: 2.9% (led to treatment adjustment in 21% of affected patients) 4
- Local injection site reactions: Skin inflammation at injection site 5
Urticaria-Specific Reactions
In chronic urticaria patients, paradoxical reactions include 6:
- Post-injection urticaria exacerbation (2.2% in mapped evidence)
- Localized urticarial plaques at injection site
- Angioedema
- Reactions occurring within minutes to one week after injection
Mechanism of Adverse Reactions
FcγR-mediated reactions: Immune complexes formed between omalizumab and IgE engage IgG receptors (FcγRs), triggering both local skin inflammation and systemic anaphylaxis 5. This explains why reactions can be delayed and why they range from injection site reactions to anaphylaxis.
Critical Clinical Implications
Mandatory Safety Measures 1:
Observation periods:
- First 3 doses: 2 hours post-injection
- Subsequent doses: 30 minutes post-injection
- This captures 75% of anaphylactic reactions 1
All patients must:
- Receive epinephrine autoinjector prescription BEFORE starting treatment
- Be trained in recognizing anaphylaxis symptoms
- Carry epinephrine for 24 hours after each injection 1
Administration requirements:
- Only by healthcare providers trained in anaphylaxis management
- In facilities equipped for anaphylaxis treatment
- Never administer at home 1
Risk Factors for Side Effects 4:
- Female sex (78.3% vs 68.6%)
- Poor disease control prior to treatment (UCT 4.0 vs 6.0)
- Lower response rates to omalizumab
Important Caveats
- The latex warning: Prefilled syringe needle cap contains natural rubber latex derivative; use autoinjector for latex-sensitive patients 2
- Pregnancy: Increased low birth weight reported (13.7% vs 9.8%), though confounded by asthma severity 2
- Treatment discontinuation: Only 2.4% discontinued due to side effects, indicating most are manageable 4
- No fatalities reported in postmarketing surveillance through 2006 1
The wide variation in reported side effects across centers (0-75.5%) suggests that awareness and reporting practices significantly influence documentation, meaning actual incidence may differ from reported rates 4.